Iovance Biotherapeutics, Inc. Stock News

SAN CARLOS, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report

Iovance Biotherapeutics, Inc. is poised to complete its rolling Biologic License Application for advanced melanoma this quarter. The recent Proleukin acquisition ensures a strong supply of IL2 for its

Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.

A business, clinical, and regulatory update lifted the spirits of investors.

After ending 2022 on a low note, U.S. market indexes continued to sink on Thursday morning after jobs data showed the labor market is still hot despite the Federal Reserve's attempts to curb inflation

In the latest conference call, Iovance Biotherapeutics, Inc. management seemed quite confident in their ability to complete the rolling of BLA for lifileucel by this quarter. I believe that previous m

Despite a rough day in the market over fears that the Federal Reserve may raise interest rates and thus induce a recession, biopharmaceutical startup Iovance Biotherapeutics (NASDAQ: IOVA ) stock shot

SAN CARLOS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou

In the latest filing, Iovance Biotherapeutics, Inc. stated that they received guidance from the FDA for lifileucel's rolling BLA. The company is expected to complete the said filing by the first quart

Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.

The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.

Shares of Iovance Biotherapeutics Inc. IOVA, -2.61% fell 11.4% in premarket trading on Friday after the company said it received feedback from the Food and Drug Administration on its submission for li

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President of Investor Relations and Corporat

SAN CARLOS, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report

Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.